Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2018
Cargando información sobre las referencias
The primary objective is to compare the efficacy of eltrombopag vs rhTPO in complete response in patients after HSCT in China. This is a post-marketing, interventional, single-center, double-arm, prospective, open-label, non-inferior, randomized controlled study in adult patients with hematopoietic stem cell transplantation in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be given eltrombopag or rhTPO under the conditions of informed consent and frequent monitoring according to the clinical guideline.
Epistemonikos ID: 905dff074f9ac7a560ace4bc521ff66d2e20e35d
First added on: May 21, 2024